- CEO
- Franciscus Lodewijk Paulus Doorenbosch
- Full Time Employees
- 907
- Sector
- Industrials
- Industry
- Manufacturing - Miscellaneous
- Address
- 47 Wates Way Mitcham SU United Kingdom CR4 4HX
- IPO Date
- May 15, 2012
- Business
- Carclo plc Carclo plc (Ticker: CCEGF) manufactures precision-engineered plastic components and assemblies for life sciences, aerospace, and optics sectors; offers in vitro diagnostics and medical devices including microfluidic components, pipettes, cuvettes, multiwells, and capillary blood sampling devices; drug delivery systems; precision injection mouldings, automation, assembly, printing, and supply chain solutions; aerospace cables, wires, machined critical components; LED lighting solutions such as aftermarket automotive lighting and Fresnel lenses; and visual aids under the Coil brand for eye care optics. The company operates through two main segments, Carclo Technical Plastics (CTP), which provides value-added engineered solutions for life science and precision industries, and the Specialty Division, which delivers components for aerospace, optical, and light & motion applications. Founded in 1924 and headquartered in Mitcham, Surrey, United Kingdom, Carclo maintains a global footprint with manufacturing facilities across EMEA, Americas, and APAC regions including the UK, Czech Republic, US (Pennsylvania), and India. Recent strategic developments include the completion of US operations restructuring with the closure of Tucson and Derry facilities in 2024-2025, consolidating manufacturing into Pennsylvania for enhanced efficiency; integration of Aerospace and Light & Motion into the Specialty Division with a refocus on higher-value precision solutions, driving 20.6% revenue growth and 19.7% return on sales in FY25; refinancing of primary borrowing facilities in April 2025 with BZ Commercial Finance DAC for a three-year £36m multi-currency agreement comprising a £27m term loan and £9m revolving credit facility; agreement on UK defined benefit pension scheme deficit recovery with a £5.1m lump sum payment and £3.5m annual contributions through 2029; expansion of strategic partnerships for process optimization, back-end automation, and material utilization improvements; a major five-year customer contract renewal in July 2025 enhancing medium-term revenue visibility; and investments in geographical expansion targeting complex precision moulding and automated assembly for in vitro diagnostics in India and South Asia.